Seer (SEER) Competitors $2.21 -0.04 (-1.78%) (As of 12/24/2024 01:48 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SEER vs. EYPT, AEHR, QTRX, SENS, NAUT, QSI, FEIM, KEQU, OPTX, and AKYAShould you be buying Seer stock or one of its competitors? The main competitors of Seer include EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quanterix (QTRX), Senseonics (SENS), Nautilus Biotechnology (NAUT), Quantum-Si (QSI), Frequency Electronics (FEIM), Kewaunee Scientific (KEQU), Syntec Optics (OPTX), and Akoya Biosciences (AKYA). These companies are all part of the "measuring and control equipment" industry. Seer vs. EyePoint Pharmaceuticals Aehr Test Systems Quanterix Senseonics Nautilus Biotechnology Quantum-Si Frequency Electronics Kewaunee Scientific Syntec Optics Akoya Biosciences EyePoint Pharmaceuticals (NASDAQ:EYPT) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking. Do insiders and institutionals have more ownership in EYPT or SEER? 99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 4.7% of EyePoint Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Seer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate EYPT or SEER? EyePoint Pharmaceuticals currently has a consensus price target of $25.71, suggesting a potential upside of 250.81%. Seer has a consensus price target of $3.00, suggesting a potential upside of 35.75%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe EyePoint Pharmaceuticals is more favorable than Seer.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EyePoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Seer 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer EYPT or SEER? In the previous week, EyePoint Pharmaceuticals and EyePoint Pharmaceuticals both had 2 articles in the media. EyePoint Pharmaceuticals' average media sentiment score of 0.40 beat Seer's score of 0.07 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment EyePoint Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seer 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is EYPT or SEER more profitable? EyePoint Pharmaceuticals has a net margin of -226.57% compared to Seer's net margin of -565.83%. Seer's return on equity of -21.96% beat EyePoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets EyePoint Pharmaceuticals-226.57% -43.01% -31.63% Seer -565.83%-21.96%-19.85% Which has better valuation and earnings, EYPT or SEER? EyePoint Pharmaceuticals has higher revenue and earnings than Seer. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyePoint Pharmaceuticals$45.71M10.94-$70.79M-$2.00-3.67Seer$14.18M9.19-$86.28M-$1.30-1.70 Does the MarketBeat Community favor EYPT or SEER? EyePoint Pharmaceuticals received 461 more outperform votes than Seer when rated by MarketBeat users. Likewise, 70.20% of users gave EyePoint Pharmaceuticals an outperform vote while only 13.64% of users gave Seer an outperform vote. CompanyUnderperformOutperformEyePoint PharmaceuticalsOutperform Votes46470.20% Underperform Votes19729.80% SeerOutperform Votes313.64%Underperform Votes1986.36% Which has more volatility & risk, EYPT or SEER? EyePoint Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. SummaryEyePoint Pharmaceuticals beats Seer on 11 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Seer News Delivered to You Automatically Sign up to receive the latest news and ratings for SEER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEER vs. The Competition Export to ExcelMetricSeerAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.32M$5.30B$5.22B$9.26BDividend YieldN/A0.43%5.12%4.29%P/E Ratio-1.7025.4187.4417.28Price / Sales9.194.261,166.50119.73Price / CashN/A44.4543.2337.83Price / Book0.362.204.834.93Net Income-$86.28M$2.05M$120.46M$225.34M7 Day Performance-2.64%-1.96%2.85%4.14%1 Month Performance-7.14%-7.54%19.70%1.16%1 Year Performance21.43%-30.22%30.57%16.98% Seer Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEERSeer1.7493 of 5 stars$2.21-1.8%$3.00+35.7%+21.4%$130.32M$14.18M-1.70160EYPTEyePoint Pharmaceuticals1.6331 of 5 stars$7.23+1.8%$25.71+255.7%-67.5%$493.46M$45.71M-3.62120AEHRAehr Test Systems2.6757 of 5 stars$14.00-1.8%$25.00+78.6%-46.3%$414.83M$58.71M14.2990QTRXQuanterix2.0798 of 5 stars$10.69+1.8%$23.25+117.5%-61.4%$410.27M$127.95M-10.18460SENSSenseonics2.2747 of 5 stars$0.47+1.2%$2.00+329.8%-21.3%$277.01M$22.21M-3.5890NAUTNautilus Biotechnology1.4617 of 5 stars$1.73-1.7%$3.58+107.1%-47.7%$217.23MN/A-3.09130High Trading VolumeQSIQuantum-Si2.0028 of 5 stars$1.31+0.8%$3.25+148.1%-30.9%$186.95M$2.27M-2.05150High Trading VolumeFEIMFrequency Electronics2.5485 of 5 stars$18.87-0.8%N/A+91.5%$181.36M$60.19M23.01200KEQUKewaunee Scientific2.2751 of 5 stars$53.49-0.7%N/A+140.7%$153.62M$199.64M8.481,006OPTXSyntec Optics0.3078 of 5 stars$3.32-5.1%N/A-38.5%$121.80M$29.39M0.003High Trading VolumeAKYAAkoya Biosciences2.0421 of 5 stars$2.36-5.2%$5.43+130.0%-51.0%$116.97M$86.82M-2.0090Positive News Related Companies and Tools Related Companies EyePoint Pharmaceuticals Alternatives Aehr Test Systems Alternatives Quanterix Alternatives Senseonics Alternatives Nautilus Biotechnology Alternatives Quantum-Si Alternatives Frequency Electronics Alternatives Kewaunee Scientific Alternatives Syntec Optics Alternatives Akoya Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEER) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seer, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
